Online Library: Glaucoma
The following pages provide an overview of the most recent research and clinical studies about the health benefits of micronutrients in fighting Glaucoma. This collection of scientific facts proves that anyone who privately or publicly questions the health value of micronutrients does not serve YOUR health, or the health of the people, but rather the multi-billion dollar investment 'business with disease' based on patented pharmaceutical drugs.
We encourage you to forward the link to this important online library on natural health – one of the largest ones in the world – to your friends. You may also print out the articles you find most important for your own health condition and share them with your doctor. Any responsibly acting health professional will be grateful to receive such science-based health education.
Effects of black currant anthocyanins on intraocular pressure in healthy volunteers and patients with glaucoma.
Affiliation: Department of Ophthalmology, Sapporo Medical University School of Medicine, Sapporo, Japan
Abstract: The purpose of the present study was to elucidate the effects of oral administration of black currant anthocyanins (BCACs) on intraocular pressure (IOP) in both healthy subjects and patients with glaucoma. (1) A placebo-controlled, double-masked, crossover study (n=12) was conducted, during which BCACs (50 mg/day) or placebos were orally administered to 12 healthy subjects once daily for 4 weeks. (2) A total of 21 glaucoma patients (BCACs, n=12; placebo, n=9) treated with a single antiglaucoma medication who had participated in a previous study were selected and analyzed. Systemic blood pressure, pulse rates, IOP, and Humphrey visual-field mean deviation (MD) were evaluated. (1) A statistically significant decrease in the mean IOP was observed at 2 weeks and 4 weeks from the baseline in BCAC-treated healthy subjects. This decrease, however, was not observed in the placebo group. In addition, at 2 weeks after the baseline, changes were also statistically significant between the groups. (2) Intergroup and between-group analyses revealed statistically significant decreases in mean IOP in the glaucoma patients taking BCACs at 24 months after the baseline. In addition, mean changes of MD deterioration were significantly less in BCAC glaucoma patients administered with BCACs at 12 months and 18 months after the baseline. No clinically significant changes were observed in systemic blood pressure or pulse rates in either trial. Conclusion: The authors’ results suggested that oral administration of BCACs may induce a beneficial decrease in IOP levels in healthy subjects as well as in patients with glaucoma.